In the last trading session, 2.87 million Syndax Pharmaceuticals Inc (NASDAQ:SNDX) shares changed hands as the company’s beta touched 0.67. With the company’s per share price at $9.30 changed hands at $0.25 or 2.76% during last session, the market valuation stood at $800.24M. SNDX’s last price was a discount, traded about -169.57% off its 52-week high of $25.07. The share price had its 52-week low at $8.58, which suggests the last value was 7.74% up since then.
Analysts gave the Syndax Pharmaceuticals Inc (SNDX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.23. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SNDX as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Syndax Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.98.
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) trade information
Instantly SNDX was in green as seen at the end of in last trading. With action -15.38%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -29.65%, with the 5-day performance at -15.38% in the red. However, in the 30-day time frame, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is -19.41% down.
The consensus price target for the stock as assigned by Wall Street analysts is 35.5, meaning bulls need an upside of 73.8% from its current market value. According to analyst projections, SNDX’s forecast low is 18 with 41 as the target high. To hit the forecast high, the stock’s price needs a -340.86% plunge from its current level, while the stock would need to soar -93.55% for it to hit the projected low.
Syndax Pharmaceuticals Inc (SNDX) estimates and forecasts
Year-over-year growth is forecast to reach 412.83% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 26.9M. 9 analysts are of the opinion that Syndax Pharmaceuticals Inc’s revenue for the current quarter will be 32.95M. The company’s revenue for the corresponding quarters a year ago was 3.5M and 12.5M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 668.56%. The estimates for the next quarter sales put growth at 163.57%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.16%. The 2025 estimates are for Syndax Pharmaceuticals Inc earnings to decrease by -1.92%, but the outlook for the next 5-year period is at 27.49% per year.
Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s Major holders
WELLINGTON MANAGEMENT GROUP LLP holds the second largest percentage of outstanding shares, with 8.6063% or 7.34 million shares worth $150.67 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. With 2.99 shares estimated at $27.78 million under it, the former controlled 3.47% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.97% of the shares, roughly 2.55 shares worth around $23.74 million.
